Eluminate-2
Research type
Research Study
Full title
A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Oral Semaglutide in Adults with Type 2 Diabetes Mellitus (Eluminate-2)
IRAS ID
1013695
Contact name
Diana Ionescu
Contact email
Sponsor organisation
AstraZeneca AB
Research summary
This is a trial to learn how safe elecoglipron is and how well it works in adults living with type 2 diabetes mellitus with increased cardiovascular risk compared to oral semaglutide.
The main purpose of this study is to find out if elecoglipron administered once daily, compared with another medicine called semaglutide, can help people with T2DM improve their overall health.
This study is "open-label," which means the study doctor and participant will know which treatment they are receiving while the study is ongoing. The participant will be randomly assigned to one of the treatment groups. This means that the treatment group participants are assigned to will be decided by chance, like tossing a coin. This helps make sure the study results are fair and unbiased.
Before starting the study treatment, the participant will have a series of assessments and tests conducted during the screening phase. These assessments and tests will check if the participant is eligible to take part in the study.
Participants who are eligible for the study will enter the titration phase; this is the first part of the treatment phase where study medication is started at a low dose, and then slowly increased step by step over several weeks (i.e. titrated), so they can safely reach their target dose. During the treatment phase, participants will remain on their target dose for the remainder of the study.
At each study visit, the study doctor will check on the participants to make sure the medication is working and that they are not having any significant side effects.REC name
London - Surrey Borders Research Ethics Committee
REC reference
26/LO/0276
Date of REC Opinion
17 Jun 2026
REC opinion
Further Information Favourable Opinion